AstraZeneca announced it has entered into a definitive agreement to acquire Modella AI, a Boston–based developer of advanced computational modeling tools for drug discovery. Modella’s platform uses physics-based simulations to predict molecular behavior and optimize candidate selection, a capability AstraZeneca expects will reduce lead identification timelines by up to 30%. The deal—subject to customary regulatory approvals—is expected to close in H1 2026, with Modella’s 60-person team joining AstraZeneca’s Global Medicines R&D organization. By integrating Modella’s predictive modeling into its existing AI framework, AstraZeneca aims to advance multiple oncology programs currently in preclinical and early-stage development, notably its next-generation ADC and bispecific antibody pipelines. No financial terms were disclosed.